EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study

Meiting Chen, Kai Yao, Manming Cao, Hao Liu, Cong Xue, Tao Qin, Lingru Meng, Zhousan Zheng, Zike Qin, Fangjian Zhou, Zhuowei Liu, Yanxia Shi und 1 weitere

Cancer Immunology, Immunotherapy · 2023-07 · 72 (7) · 2309-2318

DOI: 10.1007/s00262-023-03419-1 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 10.03.2023. Verfasst von Meiting Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cente…. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Immunoconjugates, Urinary Bladder Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phase II trials showed the efficacy of anti-HER2 RC48-ADC (disitamab vedotin) for HER2-positive metastatic urothelial carcinoma (UC). This study evaluated RC48 alone verses in combination with immunotherapy for locally advanced or metastatic UC using real-world data.

Methods

This retrospective, multicenter, real-world study included patients with locally advanced or metastatic UC who received RC48 in five hospitals in China between July 2021 and April 2022. The outcomes were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events.

Results

Thirty-six patients were included. The patients were 47–87 years, and 26 (72.2%) were male. Eighteen patients received RC48 alone, and 18 received RC48 combined with a programmed death-1 antibody. The median PFS was 5.4 months. The median OS was not reached. The 6-month and 1-year PFS rates were 38.8% and 15.5%, respectively. The 1-year OS rate was 79.6%. Fourteen (38.9%) patients achieved a partial response, and the ORR was 38.9%. Eleven patients had stable disease, and the DCR was 69.4%. The median PFS for patients who received RC48 combined with immunotherapy and those who received RC48 alone was 8.5 and 5.4 months, respectively. The main treatment-related adverse events included anemia, hypoesthesia, fatigue, and elevated transaminase. No treatment-related death occurred.

Conclusion

RC48 alone or combined with immunotherapy might benefit patients with locally advanced or metastatic UC, regardless of impaired renal function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellImmunoconjugatesUrinary Bladder NeoplasmsAntineoplastic AgentsHumansMaleFemaleRetrospective StudiesImmunotherapyAntibodies, MonoclonalOligopeptides

Stichwörter der Autor:innen

Anti-HER2 antibody–drug conjugateMetastatic urothelial carcinomaRC48Real-world study

Substanzen

ImmunoconjugatesAntineoplastic Agentsdisitamab vedotinAntibodies, MonoclonalOligopeptides

Autor:innen und Institutionen

  • Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651, Dongfeng East Road, Yuexiu District, G…
  • Department of Urology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, No. 651, Dongfeng East Road, Yuexiu District, Guangzhou,…
  • Department of Medical Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
  • Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Yuexiu District, 107 Yanjiangxi Road, Guangzhou, 510120, Guangdong, China.
  • Department of Medical Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiangxi Road, Yuexiu District, Guangzhou, 510120, Guangdong, China.
  • Ward 2, Department of Oncology, Hainan Cancer Hospital, Haikou, China.

Zitieren

APA

Chen, M., Yao, K., Cao, M., Liu, H., Xue, C., Qin, T., Meng, L., Zheng, Z., Qin, Z., Zhou, F., Liu, Z., Shi, Y., & An, X. (2023). HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. Cancer Immunology, Immunotherapy, 72(7), 2309-2318. https://doi.org/10.1007/s00262-023-03419-1

Vancouver

Chen M, Yao K, Cao M, Liu H, Xue C, Qin T, et al. HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. Cancer Immunology, Immunotherapy. 2023;72(7):2309-2318. doi:10.1007/s00262-023-03419-1

BibTeX
@article{Chen2023,
  author = {Chen, Meiting and Yao, Kai and Cao, Manming and Liu, Hao and Xue, Cong and Qin, Tao and Meng, Lingru and Zheng, Zhousan and Qin, Zike and Zhou, Fangjian and Liu, Zhuowei and Shi, Yanxia and An, Xin},
  title = {HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  volume = {72},
  number = {7},
  pages = {2309--2318},
  doi = {10.1007/s00262-023-03419-1}
}
Kostenlos starten →